NRIX - Nurix Therapeutics, Inc. Stock Price, Fair Value and News

$19.83-0.21 (-1.05%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

NRIX Price Action

Last 7 days

-2.2%

Last 30 days

-12.4%

Last 90 days

-22.6%

Trailing 12 Months

115.5%

NRIX RSI Chart

NRIX Valuation

Market Cap

1.4B

Price/Earnings (Trailing)

-7.94

Price/Sales (Trailing)

24.9

EV/EBITDA

-8.01

Price/Free Cashflow

-13.14

NRIX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

NRIX Fundamentals

NRIX Revenue

Revenue (TTM)

56.4M

Rev. Growth (Yr)

-31.84%

Rev. Growth (Qtr)

4.1%

NRIX Earnings

Earnings (TTM)

-177.0M

Earnings Growth (Yr)

-32.38%

Earnings Growth (Qtr)

-9.9%

NRIX Profitability

EBT Margin

-304.37%

Return on Equity

-46.96%

Return on Assets

-34.46%

Free Cashflow Yield

-7.61%

NRIX Investor Care

Shares Dilution (1Y)

46.04%

Diluted EPS (TTM)

-2.91

NRIX Alerts

1 major insider sales recently.

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	80.9M	62.3M	56.4M	0
2023	41.7M	60.9M	68.6M	77.0M
2022	34.4M	38.7M	39.2M	38.6M
2021	20.0M	22.9M	29.0M	29.8M
2020	24.7M	19.5M	13.0M	17.8M
2019	0	0	0	31.1M

Get all data in R, Python etc through our Historical Stock Data APIs

About Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing DeTIL-0255, a drug-enhanced investigational cell therapy product that uses NX-0255 ex vivo to enhance tumor infiltrating lymphocytes propagation and phenotypic characteristics. The company has a strategic collaboration agreement with Gilead Sciences, Inc. to discover, develop, and commercialize a pipeline of protein degradation drugs for patients with cancer and other challenging diseases; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.

CEO	Dr. Arthur T. Sands M.D., Ph.D.
WEBSITE	nurixtx.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	297

Nurix Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Nurix Therapeutics, Inc.? What does NRIX stand for in stocks?

NRIX is the stock ticker symbol of Nurix Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Nurix Therapeutics, Inc. (NRIX)?

As of Fri Dec 20 2024, market cap of Nurix Therapeutics, Inc. is 1.4 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NRIX stock?

You can check NRIX's fair value in chart for subscribers.

Is Nurix Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether NRIX is over valued or under valued. Whether Nurix Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Nurix Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NRIX.

What is Nurix Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, NRIX's PE ratio (Price to Earnings) is -7.94 and Price to Sales (PS) ratio is 24.9. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NRIX PE ratio will change depending on the future growth rate expectations of investors.